Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Jan 5. pii: annrheumdis-2018-214245. doi: 10.1136/annrheumdis-2018-214245. [Epub ahead of print]

PMID:
30612116
2.

MYH9 Associated nephropathy.

Furlano M, Arlandis R, Venegas MDP, Novelli S, Crespi J, Bullich G, Ayasreh N, Remacha Á, Ruiz P, Lorente L, Ballarín J, Matamala A, Ars E, Torra R.

Nefrologia. 2018 Nov 21. pii: S0211-6995(18)30156-5. doi: 10.1016/j.nefro.2018.08.008. [Epub ahead of print] English, Spanish.

3.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
4.

Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression.

Furlano M, Loscos I, Martí T, Bullich G, Ayasreh N, Rius A, Roca L, Ballarín J, Ars E, Torra R.

Am J Nephrol. 2018;48(4):308-317. doi: 10.1159/000493325. Epub 2018 Oct 22.

PMID:
30347391
5.

Three cases of monoclonal gammopathy of renal significance after kidney transplantation. De novo C3 glomerulopathy.

Serra N, Facundo C, Canal C, Arce Y, Ayasreh N, Vila A, Bardají B, Silva I, López V, Benito S, Ballarín J, Guirado L.

Nefrologia. 2018 Jun 15. pii: S0211-6995(18)30074-2. doi: 10.1016/j.nefro.2018.03.008. [Epub ahead of print] English, Spanish.

6.

Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome.

Debiec H, Dossier C, Letouzé E, Gillies CE, Vivarelli M, Putler RK, Ars E, Jacqz-Aigrain E, Elie V, Colucci M, Debette S, Amouyel P, Elalaoui SC, Sefiani A, Dubois V, Simon T, Kretzler M, Ballarin J, Emma F, Sampson MG, Deschênes G, Ronco P.

J Am Soc Nephrol. 2018 Jul;29(7):2000-2013. doi: 10.1681/ASN.2017111185. Epub 2018 Jun 14.

PMID:
29903748
7.

Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy.

Guillén-Gómez E, Bardají-de-Quixano B, Ferrer S, Brotons C, Knepper MA, Carrascal M, Abian J, Mas JM, Calero F, Ballarín JA, Fernández-Llama P.

J Diabetes Res. 2018 Apr 29;2018:6165303. doi: 10.1155/2018/6165303. eCollection 2018.

8.

A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases.

Bullich G, Domingo-Gallego A, Vargas I, Ruiz P, Lorente-Grandoso L, Furlano M, Fraga G, Madrid Á, Ariceta G, Borregán M, Piñero-Fernández JA, Rodríguez-Peña L, Ballesta-Martínez MJ, Llano-Rivas I, Meñica MA, Ballarín J, Torrents D, Torra R, Ars E.

Kidney Int. 2018 Aug;94(2):363-371. doi: 10.1016/j.kint.2018.02.027. Epub 2018 May 22.

PMID:
29801666
9.

Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1.

Ayasreh N, Bullich G, Miquel R, Furlano M, Ruiz P, Lorente L, Valero O, García-González MA, Arhda N, Garin I, Martínez V, Pérez-Gómez V, Fulladosa X, Arroyo D, Martínez-Vea A, Espinosa M, Ballarín J, Ars E, Torra R.

Am J Kidney Dis. 2018 Sep;72(3):411-418. doi: 10.1053/j.ajkd.2018.03.019. Epub 2018 May 18.

PMID:
29784615
10.

Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.

Marco H, Draibe J, Villacorta J, Quintana LF, Martin N, Garcia-Osuna R, Cabre C, Martín-Gómez MA, Balius A, Saurina A, Picazo M, Gich-Saladich I, Navarro-Díaz M, Praga M, Cavero T, Ballarin J, Díaz-Encarnación MM; Spanish Group for the Study of Glomerular Disease (GLOSEN).

Clin Rheumatol. 2018 Apr;37(4):1065-1074. doi: 10.1007/s10067-017-3973-2. Epub 2018 Mar 9.

PMID:
29520673
11.

Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome.

Sandoval D, Poveda R, Draibe J, Pérez-Oller L, Díaz M, Ballarín J, Saurina A, Marco H, Bonet J, Barros X, Fulladosa X, Torras J, Cruzado JM.

Clin Kidney J. 2017 Oct;10(5):632-638. doi: 10.1093/ckj/sfx035. Epub 2017 Apr 27.

12.

DNA damage in kidney transplant patients. Role of organ origin.

Corredor Z, Rodríguez-Ribera L, Coll E, Silva I, Díaz JM, Ballarín J, Marcos R, Pastor S.

Environ Mol Mutagen. 2017 Dec;58(9):712-718. doi: 10.1002/em.22117. Epub 2017 Aug 19.

PMID:
28833525
13.

Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.

DaSilva I, Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J, Praga M, Ballarín J, Díaz-Encarnación M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

BioDrugs. 2017 Jun;31(3):239-249. doi: 10.1007/s40259-017-0221-x.

PMID:
28534103
14.

Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.

Sans L, Radosevic A, Quintian C, Montañés R, Gràcia S, Vilaplana C, Mojal S, Ballarin JA, Fernández-Llama P, Torra R, Pascual J.

PLoS One. 2017 Mar 27;12(3):e0174583. doi: 10.1371/journal.pone.0174583. eCollection 2017.

15.

Vitamin E-coated dialysis membranes reduce the levels of oxidative genetic damage in hemodialysis patients.

Rodríguez-Ribera L, Corredor Z, Silva I, Díaz JM, Ballarín J, Marcos R, Pastor S, Coll E.

Mutat Res. 2017 Mar;815:16-21. doi: 10.1016/j.mrgentox.2017.01.003. Epub 2017 Feb 3.

PMID:
28283088
16.

Markers of endothelial damage in patients with chronic kidney disease on hemodialysis.

Carmona A, Agüera ML, Luna-Ruiz C, Buendía P, Calleros L, García-Jerez A, Rodríguez-Puyol M, Arias M, Arias-Guillen M, de Arriba G, Ballarin J, Bernis C, Fernández E, García-Rebollo S, Mancha J, Del Peso G, Pérez E, Poch E, Portolés JM, Rodríguez-Puyol D, Sánchez-Villanueva R, Sarro F, Torres A, Martín-Malo A, Aljama P, Ramírez R, Carracedo J.

Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F673-F681. doi: 10.1152/ajprenal.00013.2016. Epub 2017 Jan 11. Erratum in: Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F141.

17.

Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients.

Sans L, Pascual J, Radosevic A, Quintian C, Ble M, Molina L, Mojal S, Ballarin JA, Torra R, Fernández-Llama P.

Medicine (Baltimore). 2016 Dec;95(49):e5595.

18.

Levels of DNA damage in peripheral blood lymphocytes of patients undergoing standard hemodialysis vs on-line hemodiafiltration: A comet assay investigation.

Corredor Z, Rodríguez-Ribera L, Silva I, Díaz JM, Ballarín J, Marcos R, Coll E, Pastor S.

Mutat Res Genet Toxicol Environ Mutagen. 2016 Sep 15;808:1-7. doi: 10.1016/j.mrgentox.2016.07.008. Epub 2016 Jul 29.

PMID:
27637480
19.

Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications.

Bover J, Ureña-Torres P, Górriz JL, Lloret MJ, da Silva I, Ruiz-García C, Chang P, Rodríguez M, Ballarín J.

Nefrologia. 2016 Nov - Dec;36(6):597-608. doi: 10.1016/j.nefro.2016.05.023. Epub 2016 Aug 30. Review. English, Spanish.

20.

Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy.

Furlano M, Barreiro Y, Martí T, Facundo C, Ruiz-García C, DaSilva I, Ayasreh N, Cabrera-López C, Ballarín J, Ars E, Torra R.

Nefrologia. 2017 Jan - Feb;37(1):87-92. doi: 10.1016/j.nefro.2016.04.007. Epub 2016 Aug 29. English, Spanish.

21.

Detection of cardiovascular calcifications: Is it a useful tool for nephrologists?

Bover J, Górriz JL, Ureña-Torres P, Lloret MJ, Ruiz-García C, daSilva I, Chang P, Rodríguez M, Ballarín J.

Nefrologia. 2016 Nov - Dec;36(6):587-596. doi: 10.1016/j.nefro.2016.05.021. Epub 2016 Aug 27. Review. English, Spanish.

22.

Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function.

Guillén-Gómez E, Dasilva I, Silva I, Arce Y, Facundo C, Ars E, Breda A, Ortiz A, Guirado L, Ballarín JA, Díaz-Encarnación MM.

Am J Transplant. 2017 Mar;17(3):733-743. doi: 10.1111/ajt.13998. Epub 2016 Sep 15.

23.

Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.

Bover J, Ureña-Torres P, Lloret MJ, Ruiz-García C, DaSilva I, Diaz-Encarnacion MM, Mercado C, Mateu S, Fernández E, Ballarin J.

Expert Opin Pharmacother. 2016 Jun;17(9):1247-58. doi: 10.1080/14656566.2016.1182155. Epub 2016 May 13. Review.

PMID:
27156993
24.

Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.

Bover J, Ureña-Torres P, Lloret MJ, Ruiz C, DaSilva I, Diaz-Encarnacion MM, Mercado C, Mateu S, Fernández E, Ballarin J.

Expert Opin Pharmacother. 2016 Jul;17(10):1363-73. doi: 10.1080/14656566.2016.1182985. Epub 2016 May 17. Review.

PMID:
27156578
25.

Unfermented grape juice reduce genomic damage on patients undergoing hemodialysis.

Corredor Z, Rodríguez-Ribera L, Coll E, Montañés R, Diaz JM, Ballarin J, Marcos R, Pastor S.

Food Chem Toxicol. 2016 Jun;92:1-7. doi: 10.1016/j.fct.2016.03.016. Epub 2016 Mar 23.

PMID:
27016493
26.

Contribution of the TTC21B gene to glomerular and cystic kidney diseases.

Bullich G, Vargas I, Trujillano D, Mendizábal S, Piñero-Fernández JA, Fraga G, García-Solano J, Ballarín J, Estivill X, Torra R, Ars E.

Nephrol Dial Transplant. 2017 Jan 1;32(1):151-156. doi: 10.1093/ndt/gfv453.

PMID:
26940125
27.

Genetic damage in patients moving from hemodialysis to online hemodiafiltration.

Rodríguez-Ribera L, Pastor S, Corredor Z, Silva I, Diaz JM, Ballarin J, Marcos R, Coll E.

Mutagenesis. 2016 Mar;31(2):131-5. doi: 10.1093/mutage/gev063. Epub 2015 Aug 18.

PMID:
26285921
28.

Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Bover J, Ureña P, Ruiz-García C, daSilva I, Lescano P, del Carpio J, Ballarín J, Cozzolino M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):161-74. doi: 10.2215/CJN.01760215. Epub 2015 Jul 29. Review.

29.

Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated.

Cabrera-López C, Bullich G, Martí T, Català V, Ballarín J, Bissler JJ, Harris PC, Ars E, Torra R.

BMC Med Genet. 2015 Jun 17;16:39. doi: 10.1186/s12881-015-0185-y.

30.

Targeted next-generation sequencing in steroid-resistant nephrotic syndrome: mutations in multiple glomerular genes may influence disease severity.

Bullich G, Trujillano D, Santín S, Ossowski S, Mendizábal S, Fraga G, Madrid Á, Ariceta G, Ballarín J, Torra R, Estivill X, Ars E.

Eur J Hum Genet. 2015 Sep;23(9):1192-9. doi: 10.1038/ejhg.2014.252. Epub 2014 Nov 19.

31.

Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing.

Trujillano D, Bullich G, Ossowski S, Ballarín J, Torra R, Estivill X, Ars E.

Mol Genet Genomic Med. 2014 Sep;2(5):412-21. doi: 10.1002/mgg3.82. Epub 2014 May 23.

32.

Genomic damage as a biomarker of chronic kidney disease status.

Corredor Z, Stoyanova E, Rodríguez-Ribera L, Coll E, Silva I, Diaz JM, Ballarin J, Marcos R, Pastor S.

Environ Mol Mutagen. 2015 Apr;56(3):301-12. doi: 10.1002/em.21911. Epub 2014 Sep 19.

PMID:
25234591
33.

Radiosensitivity in patients suffering from chronic kidney disease.

Rodríguez-Ribera L, Corredor Z, Sandoval SB, Coll E, Silva I, Diaz JM, Ballarin J, Marcos R, Pastor S.

Int J Radiat Biol. 2015 Feb;91(2):172-8. doi: 10.3109/09553002.2015.959670. Epub 2014 Oct 16.

PMID:
25219678
34.

Renal sodium transporters are increased in urinary exosomes of cyclosporine-treated kidney transplant patients.

Esteva-Font C, Guillén-Gómez E, Diaz JM, Guirado L, Facundo C, Ars E, Ballarin JA, Fernández-Llama P.

Am J Nephrol. 2014;39(6):528-35. doi: 10.1159/000362905. Epub 2014 Jun 12.

PMID:
24942911
35.

Tables for estimating the glomerular filtration rate using the new CKD-EPI equation from serum creatinine concentration.

Canal C, Pellicer R, Facundo C, Gràcia-Garcia S, Montañés-Bermúdez R, Ruiz-García C, Furlano M, Da Silva IK, Ballarín JA, Bover J.

Nefrologia. 2014;34(2):223-9. doi: 10.3265/Nefrologia.pre2013.Dec.12226. English, Spanish.

36.

Association of C4d deposition with clinical outcomes in IgA nephropathy.

Espinosa M, Ortega R, Sánchez M, Segarra A, Salcedo MT, González F, Camacho R, Valdivia MA, Cabrera R, López K, Pinedo F, Gutierrez E, Valera A, Leon M, Cobo MA, Rodriguez R, Ballarín J, Arce Y, García B, Muñoz MD, Praga M; Spanish Group for Study of Glomerular Diseases (GLOSEN).

Clin J Am Soc Nephrol. 2014 May;9(5):897-904. doi: 10.2215/CJN.09710913. Epub 2014 Feb 27.

37.

Time in hemodialysis modulates the levels of genetic damage in hemodialysis patients.

Rodríguez-Ribera L, Stoyanova E, Corredor Z, Coll E, Silva I, Diaz JM, Ballarin J, Marcos R, Pastor S.

Environ Mol Mutagen. 2014 May;55(4):363-8. doi: 10.1002/em.21849. Epub 2014 Jan 17.

PMID:
24436196
38.

HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.

Bullich G, Ballarín J, Oliver A, Ayasreh N, Silva I, Santín S, Díaz-Encarnación MM, Torra R, Ars E.

Clin J Am Soc Nephrol. 2014 Feb;9(2):335-43. doi: 10.2215/CJN.05310513. Epub 2013 Nov 21.

39.

Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence.

Lloret MJ, Ruiz-García C, Dasilva I, Furlano M, Barreiro Y, Ballarín J, Bover J.

Patient Prefer Adherence. 2013 Nov 6;7:1147-56. doi: 10.2147/PPA.S31694. Review.

40.

Cost-effective PKHD1 genetic testing for autosomal recessive polycystic kidney disease.

Krall P, Pineda C, Ruiz P, Ejarque L, Vendrell T, Camacho JA, Mendizábal S, Oliver A, Ballarín J, Torra R, Ars E.

Pediatr Nephrol. 2014 Feb;29(2):223-34. doi: 10.1007/s00467-013-2657-7. Epub 2013 Oct 27.

PMID:
24162162
41.

Monocyte implication in renal allograft dysfunction.

Guillén-Gómez E, Guirado L, Belmonte X, Maderuelo A, Santín S, Juarez C, Ars E, Facundo C, Ballarín JA, Vidal S, Díaz-Encarnación MM.

Clin Exp Immunol. 2014 Feb;175(2):323-31. doi: 10.1111/cei.12228.

42.

Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry.

Martínez V, Comas J, Arcos E, Díaz JM, Muray S, Cabezuelo J, Ballarín J, Ars E, Torra R.

BMC Nephrol. 2013 Sep 5;14:186. doi: 10.1186/1471-2369-14-186.

43.

Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol).

Bover J, Dasilva I, Furlano M, Lloret MJ, Diaz-Encarnacion MM, Ballarin J, Cozzolino M.

Curr Vasc Pharmacol. 2014 Mar;12(2):313-23. Review.

PMID:
23713879
44.

Mycophenolate as maintenance therapy for lupus nephritis with impaired renal function.

Rivera F, Illescas ML, López-Rubio E, Fulladosa J, Poveda R, Baltar J, Fernández-Juárez G, Ballarín J, Oliet A, Vigil A, Lucas J, Sierra M, Frutos MA, García-Frías P, Ramos C, Mérida E, Praga M, Segarra A.

Am J Nephrol. 2013;37(6):509-17. doi: 10.1159/000350756. Epub 2013 May 8.

PMID:
23689615
45.

Genomic damage as an independent predictor marker of mortality in hemodialysis patients.

Coll E, Stoyanova E, Rodríguez-Ribera L, Solozábal M, Pastor S, Silva I, Diaz JM, Ballarin J, Xamena N, Marcos R.

Clin Nephrol. 2013 Aug;80(2):81-7. doi: 10.5414/CN107719.

PMID:
23587126
46.

Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation.

Marco H, Mirapeix E, Arcos E, Comas J, Ara J, Gil-Vernet S, Puig J, Vinyas O, Perello M, Oppenheimer F, Poveda R, Ibernón M, Díaz M, Ballarin J; Catalan Study Group of Glomerular Diseases (GLOMCAT).

Clin Transplant. 2013 May-Jun;27(3):338-47. doi: 10.1111/ctr.12084. Epub 2013 Feb 20.

PMID:
23421384
47.

Recombinant PTH associated with hypercalcaemia and renal failure.

Ayasreh N, Fernandez-Llama P, Lloret MJ, Da Silva I, Ballarín J, Bover J.

Clin Kidney J. 2013 Feb;6(1):93-95. Epub 2012 Nov 15. No abstract available.

48.

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial.

Cabrera-López C, Martí T, Catalá V, Torres F, Mateu S, Ballarín J, Torra R.

Orphanet J Rare Dis. 2012 Nov 11;7:87. doi: 10.1186/1750-1172-7-87.

49.

Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria.

Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, Olea T, Martínez-Ara J, Segarra A, Bernis C, García A, Goicoechea M, García de Vinuesa S, Rojas-Rivera J, Praga M; Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN).

J Am Soc Nephrol. 2012 Oct;23(10):1753-60. Epub 2012 Sep 6.

50.

Angioplasty and stent treatment of transplant renal artery stenosis.

Del Pozo M, Martí J, Guirado L, Facundo C, Canal C, de la Torre P, Ballarín J, Díaz JM.

Nefrologia. 2012 Jul 17;32(4):455-8. doi: 10.3265/Nefrologia.pre2012.Jan.11080. English, Spanish.

Supplemental Content

Loading ...
Support Center